Clik here to view.
Cellusion raises 2.83 Billion Yen (21 Million USD) in Series C Round
TOKYO Cellusion Inc. (Head Office: Tokyo; CEO: Shin Hatou; hereinafter referred to as “Cellusion”) announced that it has raised 2.83 billion yen (21 million USD) in Series C Round financing. New...
View ArticleClik here to view.
Novaliq宣布VEVYE™ 0.1%（环孢素滴眼液）获得FDA批准，用于治疗干眼症的症状和体征
德国海德堡和美国马萨诸塞州剑桥 (美国商业资讯)–专注于业内首创和一流的眼科治疗药物的生物制药公司Novaliq GmbH今天宣布，美国食品药品管理局(FDA)已批准VEVYE™ 0.1%（环孢素滴眼液）用于治疗干眼症的症状和体征。VEVYE（开发名CyclASol®）是首创且唯一一款用于治疗干眼症症状和体征的环孢素溶液，在治疗四周后展现出疗效。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03...
OSAKA, Japan & HEIDELBERG, Germany & CAMBRIDGE, Mass. Senju Pharmaceutical Co., Ltd., a researched-based Japanese pharmaceutical company focusing the field of ophthalmology, and Novaliq...
View ArticleClik here to view.
CORRECTING and REPLACING Senju Pharmaceutical and Novaliq Enter Into License...
OSAKA, Japan & HEIDELBERG, Germany & CAMBRIDGE, Mass. Fifth paragraph, the number in the quote should read: 10 million units sold instead of 10,000 million units sold. The updated release...
View ArticleClik here to view.
Senju Pharmaceutical和Novaliq达成许可协议，将NOV03（全氟己基辛烷滴眼液）用于日本干眼症治疗
日本大阪、德国海德堡和马萨诸塞州剑桥 (美国商业资讯)– Senju Pharmaceutical Co., Ltd.是一家专注于眼科领域的日本研究型制药公司。生物制药公司Novaliq...
View ArticleClik here to view.
EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret™ in...
LONDON & NEW YORK Eyebiotech Limited (EyeBio), a clinical-stage ophthalmology biotechnology company, today announced the dosing of the first participants in its Phase 1b/2 AMARONE...
View ArticleClik here to view.
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active...
DUBLIN Horizon Therapeutics plc (Nasdaq: HZNP) today announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA for the treatment of active TED. TEPEZZA is the first and only...
View ArticleClik here to view.
Santen Agrees to Licensing Agreements and Asset Transfer for its...
OSAKA, Japan Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies. Santen has come to an...
View ArticleClik here to view.
欧洲药品管理局接受Novaliq的0.1% CyclASol®（环孢霉素眼用溶液）治疗干眼病的上市许可申请
德国海德堡和美国马萨诸塞州剑桥 (美国商业资讯)– 专注于一流眼部治疗方案的生物制药公司Novaliq GmbH今天宣布，欧洲药品管理局（European Medicines Agency，EMA）已接受CyclASol（环孢素眼用溶液）的上市授权申请（marketing authorization...
View ArticleClik here to view.
Kubota Vision Announces Collaborative Research Agreement with China Medical...
SEATTLE Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo...
View ArticleClik here to view.
Half a Million Factory Workers in Low-Income Countries Have Vision Screened...
NEW YORK On World Sight Day, an annual day of awareness to focus on vision impairment and eye health, the social enterprise VisionSpring has announced that it has screened the vision of half a...
View ArticleClik here to view.
Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 / 2 Clinical Trial
SEATTLE & CAMBRIDGE, Mass. & TOKYO Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the...
View ArticleClik here to view.
Lubrizol’s Apisolex™ Polymer Wins Finished Formulation Award at CPhI Barcelona
CLEVELAND Lubrizol Life Science Health, a leading pharmaceutical company, has won the Finished Formulation Award at CPhI Barcelona for its innovative technology – Apisolex™ Polymer solubilizing...
View ArticleClik here to view.
RMK Launches Color Blind Glasses ‘Dalton’
SEJONG, South Korea RMK Inc., established as a venture company for the colorblind, launched “Dalton,” a sunglass designed for color blindness correction. Dalton comes with a colorblindness...
View ArticleClik here to view.
FDA Grants Breakthrough Device Status to Toku’s Patented Cardiovascular Risk...
AUCKLAND, New Zealand Toku, Inc., a commercial medical device company specializing in imaging technology and AI, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
View ArticleClik here to view.
Aurion Biotech Named “Regenerative Therapeutics Company Of The Year” By...
SEATTLE & CAMBRIDGE & TOKYO Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced it has been selected as...
View ArticleClik here to view.
VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells,...
KOBE, Japan VCCT Inc.(President: Masayo Takahashi) is pleased to announce the completion of a private equity allotment of approximately 600 million yen ($4 million USD). The allotment involved new...
View ArticleClik here to view.
OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy...
SUWON, South Korea OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive results from a Phase 1 study evaluating the safety and tolerability...
View ArticleClik here to view.
RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA...
TOKYO RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that the Eye has published full results from the phase 1 (SUSHI) and...
View ArticleClik here to view.
Kubota Vision Announces Vendor Agreement with IQVIA for eyeMO
SEATTLE Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo...
View Article